[go: up one dir, main page]

WO2018195765A1 - Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir) - Google Patents

Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir) Download PDF

Info

Publication number
WO2018195765A1
WO2018195765A1 PCT/CN2017/081829 CN2017081829W WO2018195765A1 WO 2018195765 A1 WO2018195765 A1 WO 2018195765A1 CN 2017081829 W CN2017081829 W CN 2017081829W WO 2018195765 A1 WO2018195765 A1 WO 2018195765A1
Authority
WO
WIPO (PCT)
Prior art keywords
exon
sequence
pcr
sbt
primer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/081829
Other languages
English (en)
Chinese (zh)
Inventor
邓志辉
甄建新
张国彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENZHEN BLOOD CENTER
Original Assignee
SHENZHEN BLOOD CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHENZHEN BLOOD CENTER filed Critical SHENZHEN BLOOD CENTER
Priority to PCT/CN2017/081829 priority Critical patent/WO2018195765A1/fr
Publication of WO2018195765A1 publication Critical patent/WO2018195765A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Definitions

  • the invention relates to the field of biomedical, in particular DNA sequencing, typing.
  • the invention provides a method for simultaneous amplification and simultaneous sequencing of all 14 functional KIRs genes suitable for high-pass quantification.
  • KIRs Killer immunoglobulin-like receptors
  • NK cells natural killer cells
  • T cells T cells
  • KIR2D and KIR3D subfamilies According to the length of cytoplasmic region and the presence or absence of immunoreceptor tyrosine inhibitory motif (ITIM), KIR is functionally divided into inhibitory type (L type). ) and activation type (S type).
  • L type inhibitory type
  • S type activation type
  • KIR molecules bind to HLA class antigens on the surface of target cells, conduct activation or inhibition signals, regulate the activity of NK cells, and play an important role in transplantation immunity, tumor immunity and anti-infection.
  • the KIR gene family is located on human chromosome 19 and is codominantly expressed. In addition to the two pseudogenes 2DP1 and 3DP1, it also includes 14 functional KIR genes (KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1) [1] .
  • the structure of KIR gene is complex: in addition to KIR3DL3 deletion of exon 6 in the functional KIR3D gene, the remaining functional KIR3D genes (3DL1, 3DL2, 3DS1) contain 9 exons, 8 introns and 5'- The promoter region and the 3'-UTR region.
  • Each exon encodes a different peptide domain, wherein the first exon and the second exon encode a leader peptide, and the third exon, the fourth exon, and the fifth exon encode an extracellular region, respectively.
  • the D0, D1, D2 domains, the 6th exon encodes the stem domain, the 7th exon encodes the transmembrane region, the 8th exon and the 9th exon encode the cytoplasmic region; in the KIR2D gene,
  • the third exon of eight genes, such as KIR2DS1 ⁇ 3 and 2DS1 ⁇ 5, is a pseudoexon, which cannot encode the corresponding D0 extracellular domain; KIR2DL4 and 2DL5 all lack the fourth exon, and no D1 cell Outer domain.
  • the total length of the included KIR genome sequence is 9901 to 17009 bp.
  • the coding sequence (CDS) of each functional KIR gene is only 915 to 1368 bp in length (see Table 3), while the non-coding region sequence is 8773 to 15641 bp (see Table 4).
  • the lengths of the 5th intron and the 6th intron of the wings of the 6th exon accounted for 44.0% to 61.2% of the corresponding full length sequence of the KIR genome (see Table 4).
  • the first exon (34 or 40 bp in length) and the second exon (36 bp in length) of the functional KIR gene are short in length and limited in polymorphism of SNPs: 2DL2, 2DL4 and 2DS4 genes first and second There are no SNPs polymorphism in exons, and the remaining ones have 1 to 3 SNPs.
  • the first intron between the first exon and the second exon has a length of 199 to 2280 bp. Due to the short length of the first and second exons and the limited polymorphism of SNPs, not every KIR gene needs to be detected during routine sequencing. For the necessary detection, PCR amplification should be performed separately, and the PCR amplification products cover the complete The 1 exon, the 1st intron and the 2nd exon do not cause the amplified product fragment to be too long.
  • each exon has a relatively long length (282-300 bp), and the SNPs are polymorphic, and should cope with exons and exons encoding the extracellular domain.
  • the introns were subjected to separate PCR amplification.
  • the third exon of 8 genes of KIR2DL1 ⁇ 3 and KIR2DS1 ⁇ 5 is a pseudo exon, no amplification is required, and the amplified product covers the complete 4th exon, 4th intron and 5th exon.
  • the 4th and 5th exons are sequenced bidirectionally; KIR2DL4 and 2DL5 have no exon 4, and the amplified product covers the complete exon 3, exon 5 and introns in between.
  • the 6th exon (KIR3DL3 lacks the exon), the length is only 51 bp, based on the IPD-KIR Database (Release 2.6.0), the 4th exon of the 4 KIR genes (2DS4, 3DL1, 3DL2 and 3DS1) There are no SNPs, and the remaining functional KIR genes have 1 or 2 SNPs. Due to the limited distribution of the SNPs in the 6th exon, and located in the first The 5th and 6th intron sequences of the 6 exons are as long as 4937 ⁇ 9841bp (see Table 4). Therefore, the polymorphism of the 6th exon must be detected, and the exon 6 must be amplified by PCR. In order to avoid amplification of the entire sequence of the 5th intron and/or the 6th intron, the amplified product fragment is too long, the amplification time is too long, and the amplification efficiency is affected.
  • the lengths of the 7th, 8th, and 9th exons are 102 to 105 bp, 51 to 53 bp, and 8 to 270 bp, respectively, and the lengths of the 7th and 8th introns are 460 to 462 bp and 98 to 118 bp, respectively. Therefore, amplification of the entire exon 7, the 7th intron, the 8th exon, the 8th intron, and the 9th exon sequence does not cause the amplified product fragment to be too long.
  • the structure of the full-length sequence of the genome based on all of the above functional KIR genes, the distribution of SNPs polymorphisms, and the length of the exon two-wing introns are essential for the development of a scientific and efficient PCR amplification strategy.
  • the polymorphism of the KIR gene is reflected in the KIR allele polymorphism and haploid composition.
  • the total number of functional KIR alleles published by the International IPD-KIR Database (Release 2.6.0) has reached 698, of which 7 KIR alleles are not expressed; among the 14 functional KIR genes, The most polymorphic KIR3DL2 has 112 alleles (Table 5).
  • affinities, and mediated activation/inhibition abilities of different alleles in the same KIR gene There are also differences in the expression levels, affinities, and mediated activation/inhibition abilities of different alleles in the same KIR gene.
  • KIR3DL1*01502>*020>*001>*007>*005 the expression level of KIR3DL1 allele on NK cell membrane was from high to low: KIR3DL1*01502>*020>*001>*007>*005, and the mediated inhibitory effect was: KIR3DL1*001>*005>*01502>*020>*007; KIR3DL1*005 has a low expression level on the cell surface, but has a strong mediated inhibition ability.
  • the most common KIR3DL1*004 allele in the Caucasian population is not expressed on the cell surface [5] .
  • KIR2DS4*003, *004, *006, *007, *008, *009, *010, *012, and *013 have a 22bp deletion in the 5th exon CDS nt454 ⁇ nt475 position, causing the reading frame shift, coding Truncated peptides are not normally expressed on the cell surface [6] .
  • the expression levels and mediated activation/inhibition abilities of different alleles in the same KIR gene are also different. It is necessary to identify and screen common KIR alleles without activation/inhibition effects. . It is especially urgent to study and establish a high-throughput, high-resolution KIR gene simultaneous sequencing method, and to carry out KIR application research based on the allele level.
  • PCR-SSOP sequence specific primer-polymerase chain reaction
  • sequence specific oligonucleotide probe-PCR sequence specific oligonucleotide probe-PCR
  • the sequence-based typing (SBT) method is the gold standard for genotyping.
  • KIR sequencing typing kit and corresponding analysis software for determining KIR genotype there is no internationally recognized KIR gene sequencing method. Since the KIR allele sequence is highly homologous and the sequence of the intron in the full length sequence of the genome is particularly long, it is very difficult to specifically PCR amplification of the KIR gene.
  • the KIR sequencing typing method has been reported to have the following problems: (1) only some exons of the KIR gene have been sequenced [7, 8, 9] , and the complete coding region sequence and analysis of the external display cannot be obtained. The polymorphism of the sub-segment is prone to ambiguous sequencing typing results.
  • the target gene fragment amplified by PCR during sequencing typing covers all the coding regions, but the amplified product fragments are too long, such as the amplification of KIR3DS1 exon 3 to 3'-UTR gene fragment up to 12.2 Kb, the 68 °C chain extension time in a single cycle is 13 min [10] , the time required for amplification is more than 10 hours, and the requirements for sample DNA quality and DNA polymerase are very high.
  • the sequence of the KIR gene is highly homologous, and the PCR primers for amplifying the target gene fragment sometimes have non-specific amplification/co-amplification, for example, the subject carries the KIR2DL1 and 2DS1 genes, and the 2DL1 is amplified.
  • PCR primers are designed to be double-amplified by nested PCR, and the experimental operation is cumbersome [11] .
  • the extension time is different due to the difference in annealing temperature of PCR primers and the difference in length of PCR gene amplification [10,11,12] .
  • PCR simultaneous amplification and simultaneous sequencing under the same cycle parameters can not achieve high-pass quantification, and the experiment is time-consuming and laborious [13] .
  • KIR has become more and more widely used in the field of application, and it has established a high-efficiency, low-cost, functional KIR gene synchronization sequencing type suitable for Qualcomm quantification.
  • the method and commercialization and industrialization are the problems that need to be solved urgently.
  • the present invention aims to solve the above problems, and for the first time provides a method for synchronizing sequencing of 14 functional killer cell immunoglobulin-like receptors (KIRs) genes, which can be widely applied to population genetics, bone marrow transplantation tissue matching. Research areas such as disease association, and lay the foundation for the commercialization of KIR gene sequencing and typing reagents, and change the current status of the international KIR-free sequencing and typing reagents.
  • KIRs killer cell immunoglobulin-like receptors
  • the coding region sequence of the 2DL1 gene is amplified by using 5 pairs of 2DL1 gene-specific PCR primers; wherein the first pair of PCR primers amplifies the first exon, the first intron, the second exon of the 2DL1 gene, and a portion of the 5'-promoter region and a portion of the second intron; the second pair of PCR primers amplify the 4th exon of 2DL1 and a partial sequence of its flanking; the third pair of PCR primers amplifies the 5th of 2DL1 a partial sequence of the exon and its flanks; a fourth pair of PCR primers amplifies the 6th exon of 2DL1 and a partial sequence of its flanking; the fifth pair of PCR primers amplifies the 7th exon of 2DL1, 7th Intron, 8th exon, 8th intron, ninth exon, and part 6 intron and part 3'UTR Sequence of regions;
  • the coding regions of the 2DL2, 2DL3, 2DS1, 2DS2, 2DS3, 2DS4 and 2DS5 genes were amplified by four pairs of KIR gene-specific PCR primers; the first pair of PCR-specific primers amplified the first exon, the first The intron and the second exon, and the sequence of the partial 5'-promoter region and part of the second intron; the second pair of PCR-specific primers amplify the fourth exon, the fourth intron, the first 5 exons, and some 2/3 introns (because the third exon is a pseudo exon, the sequence between the second exon and the fourth exon is collectively referred to as the 2/3 inclusive) And a part of the 5th intron; the third pair of PCR-specific primers amplify the partial sequence of the exon 6 and its flanking; the fourth pair of PCR-specific primers amplifies the exon 7 and the 7th Sequences of an intron, an 8th exon, an 8th intron, a 9
  • the coding sequences of the 2DL4 and 2DL5 genes were amplified by four pairs of KIR gene-specific PCR primers; the first pair of PCR-specific primers amplified the first exon, the first intron, and the second exon. And a portion of the 5'-promoter region and a portion of the second intron; the second pair of PCR-specific primers amplify the third exon, the 3/4 intron (due to the deletion of the fourth exon, the first The sequence between exon 3 and exon 5 is collectively referred to as the 3/4 intron), the exon 5, and the sequence of part of the second intron and part of the 5th intron;
  • the PCR-specific primers amplify the partial sequence of the exon 6 and its flanks; the fourth pair of PCR-specific primers amplify the 7th exon, the 7th intron, the 8th exon, and the 8th a sequence comprising a subunit, a ninth exon, and a portion of the sixth intron
  • the coding regions of the 3DL1, 3DL2 and 3DS1 genes were amplified by four pairs of KIR gene-specific PCR primers; the first pair of PCR-specific primers amplified the first exon, the first intron, and the second exon.
  • the second pair of PCR-specific primers amplify the third exon, the third intron, the fourth exon, and the fourth a sequence containing a sub-operon, a fifth exon, and a portion of the second intron and a portion of the fifth intron;
  • a third pair of PCR-specific primers amplifying a partial sequence of the exon 6 and its flanks; Amplification of the 7th exon, the 7th intron, the 8th exon, the 8th intron, the 9th exon, and some of the 6th intron and part of the 3'UTR region by PCR-specific primers the sequence of;
  • the coding region of the 3DL3 gene was amplified by the exon 6 and the exon was not amplified. Only 3 pairs of 3DL3 gene-specific PCR primers were used for amplification; the first pair of PCR-specific primers amplified the first The sequence of the exon, the first intron, the second exon, and the partial 5'-promoter region and part of the second intron; the second pair of PCR-specific primers amplifies the third exon, the third Sequence of intron, 4th exon, 4th intron, 5th exon, and part 2nd intron and part 5 intron; 3rd PCR specific primer amplification 7th Sequences of an exon, a 7th intron, an 8th exon, an 8th intron, a 9th exon, and a portion of the 6th intron and a portion of the 3' UTR region.
  • the first pair of PCR primers that amplify the entire coding region of the KIR2DL1 gene include the upstream primer 2DL1_PCR_Ex12_F (sequence: 5'-GTTCGGGAGGTTGGATCTC-3', the position in the full length sequence of the genome: nt-268 to nt-250) and the downstream primer 2DL1_PCR_Ex12_R (sequence: 5'-CACACTGCAGCCCCTACCG-3', nt1332 to nt1350), specifically amplifying the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part
  • the sequence of the 2 introns, the length of the amplified fragment of interest is 1618 bp.
  • the second pair of PCR primers include the upstream primer 2DL1_PCR_Ex4_F (sequence: 5'-TGATTCTCCTGAGTCTCCAGAGG-3', nt2501 to nt2523) and the downstream primer 2DL1_PCR_Ex4_R (sequence: 5'-TGGAAGGAGAAGAGGCAGTTTCC-3', nt5288 to nt5310), specific
  • the 4th exon and its partial flanking sequences were amplified, and the amplified fragment of interest was 2810 bp.
  • the third pair of PCR primers includes 2DL1_PCR_Ex5_F (sequence: 5'-CTGGCAGGGACCTACAGATGC-3', nt3692 ⁇ nt3712) and downstream primer 2DL1_PCR_Ex5_R (sequence: 5'-GGACAGCCATGGGCTTTCCTC-3', nt5608 ⁇ nt5628), specific amplification of the fifth explicit
  • 2DL1_PCR_Ex5_F sequence: 5'-CTGGCAGGGACCTACAGATGC-3', nt3692 ⁇ nt3712
  • 2DL1_PCR_Ex5_R sequence: 5'-GGACAGCCATGGGCTTTCCTC-3', nt5608 ⁇ nt5628
  • the fourth pair of PCR primers includes the upstream primer 2DL1_PCR_Ex6_F (sequence: 5'-TCCTGATTGTGAGTTCTTGGCAT-3', nt8082 to nt8104) and the downstream primer 2DL1_PCR_Ex6_R (sequence: 5'-TGAGTCAGTSAGTCGAARTGTGC-3', nt9279 to nt9301), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 1220 bp.
  • the fifth pair of PCR primers includes the upstream primer 2DL1_PCR_Ex789_F (sequence: 5'-CCTCAGCACGTTCTATGGTTACT-3', nt12880-nt12902) and the downstream primer 2DL1_PCR_Ex789_R (sequence: 5'-TGTGATTGCAGCCTCAAGTAGAC-3', nt14249-nt14271), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest The length is 1392 bp.
  • the first pair of PCR primers that amplify the entire coding region of the KIR2DL2 gene include the upstream primer 2DL2_PCR_Ex12_F (sequence: 5'-AGAGGTTGGATCTGAGACGTC-3', nt-263-nt-243) and the downstream primer 2DL2_PCR_Ex12_R (sequence: 5'-GGACCGATGGAGAAGTTGGCT -3', nt3590 to nt3610), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, The amplified fragment was 3873 bp in length.
  • the second pair of PCR primers include the upstream primer 2DL2_PCR_Ex45_F (sequence: 5'-GAGGCTACTAGAGACAGAGGGAC-3', nt3207-nt3229) and the downstream primer 2DL2_PCR_Ex45_R (sequence: 5'-CCCAAGCTTCGTCTTCTCTCT-3', nt5617-nt5637), specific amplification 4
  • the sequence of the exon, the 4th intron, the 5th exon, and part of the 2/3 intron and part of the 5th intron, the amplified fragment of interest is 2431 bp.
  • the third pair of PCR primers includes the upstream primer 2DL2_PCR_Ex6_F (sequence: 5'-CATGCCAACATCATGCTGTC-3', nt8530 ⁇ nt8549) and downstream primer 2DL2_PCR_Ex6_R (sequence: 5'-TCCCTGTCCTAGCCTCCATAC-3', nt9879 ⁇ nt9899), specifically amplifying the partial sequence of exon 6 and its flanks, The amplified fragment was 1370 bp in length.
  • the fourth pair of PCR primers includes the upstream primer 2DL2_PCR_Ex789_F (sequence: 5'-GAAGTTCCACTTGCCAAGGAATG-3', nt9210 ⁇ nt9232) and the downstream primer 2DL2_PCR_Ex789_R (sequence: 5'-CAGCTGCTGGTACATGGGAGC-3', nt14071-nt14091), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 4882 bp.
  • the first pair of PCR primers that amplify the entire coding region of the KIR2DL3 gene include the upstream primer 2DL3_PCR_Ex12_F (sequence: 5'-GGCYGMCTGTCTGCACAGA-3', nt-26 to nt-8) and the downstream primer 2DL3_PCR_Ex12_R (sequence: 5'-GGTTTCCTGTTGCTGCTGTAG -3', nt2560 to nt2580), specific amplification of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, the purpose
  • the amplified fragment was 2606 bp in length.
  • the second pair of PCR primers includes the upstream primer 2DL3_PCR_Ex45_F (sequence: 5'-AGAGAAGAGGGAGGGAGACAGAT-3', nt3231 to nt3253) and the downstream primer 2DL3_PCR_Ex45_R (sequence: 5'-GCCATCCTGTGCCCTGATC-3', nt5651 to nt5669), specific amplification 4
  • the sequence of the exon, the 4th intron, the 5th exon, and part of the 2/3 intron and part of the 5th intron, the amplified fragment of interest is 2439 bp in length.
  • the third pair of PCR primers include the upstream primer 2DL3_PCR_Ex6_F (sequence: 5'-CCCACCTCAGGCTCTCAAAGG-3', nt7497-nt7517) and the downstream primer 2DL3_PCR_Ex6_R (sequence: 5'-GGCGTACAATGTCAGAGCTGC-3', nt8908-nt8928), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 1432 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DL3_PCR_Ex789_F (sequence: 5'-ACTGAGAAAGCAGGAGAAAGCTG-3', nt12934-nt12956) and the downstream primer 2DL3_PCR_Ex789_R (sequence: 5'-CCTTCAGATTCCAGCTGCTGG-3', nt14063-nt14083), specific amplification of exon 7, intron 7, exon 8, intron, ninth exon, and part
  • the sequence of the 6 intron and part of the 3'-untranslated region, the length of the amplified fragment of interest is 1150 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DL4 gene includes the upstream primer 2DL4_PCR_Ex12_F (sequence: 5'-GTGGTCAATGTGTCAACTGCACG-3', nt-99-nt-77) and the downstream primer 2DL4_PCR_Ex12_R (sequence: 5'-CACAGGCTCCAAGGATTACAATG) -3', nt1639 to nt1661), specific amplification of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, the purpose
  • the amplified fragment was 1760 bp in length.
  • the second pair of PCR primers include the upstream primer 2DL4_PCR_Ex35_F (sequence: 5'-CTTTCTTCCCCATGGCTGAGTTG-3', nt571-nt593) and the downstream primer 2DL4_PCR_Ex35_R (sequence: 5'-CTTGGGCAACAAGAGTGAAACGC-3', nt3848-nt3870), specific amplification 3
  • the sequence of the exon, the 3/4 intron, the 5th exon, and part of the 2nd intron and part of the 5th intron, the amplified fragment of interest is 3300 bp.
  • the third pair of PCR primers includes the upstream primer 2DL4_PCR_Ex6_F (sequence: 5'-AACCTCTACCTCCAGGATTCAAG-3', nt3904-nt3926) and the downstream primer 2DL4_PCR_Ex6_R (sequence: 5'-GTAAGTGGAAGTGTCATGTGCAC-3', nt5738-nt5760), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 1857 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DL4_PCR_Ex789_F (sequence: 5'-CCAAGAAATGAGAGACAATCCAC-3', nt9442 to nt9464) and the downstream primer 2DL4_PCR_Ex789_R (sequence: 5'-AGGCACCAGATTTGTGGTGTG-3', nt10540 to nt10560), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest The length is 1119 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DL5 gene includes the upstream primer 2DL5_PCR_Ex12_F (sequence: 5'-TCATAGTGAAGGACGYGAGGTGC-3', nt-230 to nt-208) and downstream introduction.
  • 2DL5_PCR_Ex12_R (sequence: 5'-AGCCAATGTGTGAACCACAATAC-3', nt1238 ⁇ nt1260), specifically amplifying the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part
  • the sequence of the second intron, the amplified fragment of interest is 1490 bp in length.
  • the second pair of PCR primers include the upstream primer 2DL5_PCR_Ex35_F (sequence: 5'-CAGGACAAGCCCTTGCTGTCT-3', nt1571 to nt1591) and the downstream primer 2DL5_PCR_Ex35_R (sequence: 5'-GACAGAAACAAGCAGTGGGTCAC-3', nt2993 to nt3015), specific amplification 3
  • the sequence of the exon, the 3/4 intron, the 5th exon, and part of the 2nd intron and part of the 5th intron, the amplified fragment of interest is 1445 bp.
  • the third pair of PCR primers include the upstream primer 2DL5_PCR_Ex6_F (sequence: 5'-CATTTCCTCACCTCTCTCCTGTCCT-3', nt5158-nt5182) and the downstream primer 2DL5_PCR_Ex6_R (sequence: 5'-AAGAGCAGAGGCCAAATGCATCG-3', nt6351 to nt6373), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 1216 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DL5_PCR_Ex789_F (sequence: 5'-CAGATGTTGTATGTGCTTAGCTG-3', nt7907-nt7929) and the downstream primer 2DL5_PCR_Ex789_R (sequence: 5'-GGTTTTGAGACAGGGCTGTTGTC-3', nt8937-nt8959), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 1053 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DS1 gene includes the upstream primer 2DS1_PCR_Ex12_F (sequence: 5'-CATAGTGAAGGACGCTAGGTGTA-3', nt-229-nt-207) and the downstream primer 2DS1_PCR_Ex12_R (sequence: 5'-GAGCCCTCTGACCTGTGACCG -3', nt2035-nt2055), specific amplification of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, the purpose
  • the amplified fragment was 2284 bp in length.
  • the second pair of PCR primers includes the upstream primer 2DS1_PCR_Ex45_F (sequence: 5'-GTTCCTCTTCCACCCCCACAC-3', nt3175 to nt3195) and the downstream primer 2DS1_PCR_Ex45_R (sequence: 5'-GAGGGTTTGGAGGTGCCCTGTCG-3', nt5747-nt5769), specifically amplifying the 4th exon, the 4th intron, the 5th exon, and part of the 2/3 intron and The sequence of part of the 5th intron, the length of the amplified fragment of interest is 2595 bp.
  • the third pair of PCR primers include the upstream primer 2DS1_PCR_Ex6_F (sequence: 5'-TCCTGATTGTGAGTTCTTGGCAT-3', nt8078-nt8100) and the downstream primer 2DS1_PCR_Ex6_R (sequence: 5'-GTCTCCTAGATTCCAGTTACGCC-3', nt10742-nt10764), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 2687 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DS1_PCR_Ex789_F (sequence: 5'-CGTGGAAAAGGCAATTCCCGA-3', nt10765-nt10785) and the downstream primer 2DS1_PCR_Ex789_R (sequence: 5'-GGAGGTGGAACAGCACGTGTC-3', nt14330-nt14350), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest The length is 3586 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DS2 gene includes the upstream primer 2DS2_PCR_Ex12_F (sequence: 5'-TGAGAGGTTGGATCTGAGACGTC-3', nt-265-nt-243) and the downstream primer 2DS2_PCR_Ex12_R (sequence: 5'-ACATCCAGGCTCTTATCAGCCTT -3', nt2956-nt2978), specific amplification of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, the purpose
  • the amplified fragment was 3243 bp in length.
  • the second pair of PCR primers includes the upstream primer 2DS2_PCR_Ex45_F (sequence: 5'-GCTTCCATGCTTCTGATAATTTTG-3', nt2420 ⁇ nt2443) and the downstream primer 2DS2_PCR_Ex45_R (sequence: 5'-CTCTGGGTCTCTCCTGACCGT-3', nt5639 ⁇ nt5659), specific amplification 4
  • the sequence of the exon, the fourth intron, the exon 5, and part of the 2/3 intron and part of the 5th intron, the amplified fragment of interest is 3240 bp in length.
  • the third pair of PCR primers includes the upstream primer 2DS2_PCR_Ex6_F (sequence: 5'-CATTCTGCTCCGTTGTTCTATGTC-3', nt8282 to nt8305) and the downstream primer 2DS2_PCR_Ex6_R (sequence: 5'-GCCAGGGTTGCTTCATGACCTAT-3', Nt9024 ⁇ nt9046) specifically amplified the partial sequence of exon 6 and its flanks, and the amplified fragment of interest was 765 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DS2_PCR_Ex789_F (sequence: 5'-GATAGGCCATGGGGAGGTAAATT-3', nt11463-nt11485) and the downstream primer 2DS2_PCR_Ex789_R (sequence: 5'-GGGCAGACATGTTTATTTGAAGGC-3', nt14250-nt14273), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 2811 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DS3 gene includes the upstream primer 2DS3_PCR_Ex12_F (sequence: 5'-TGTAAACTGCATGGGCAGGGA-3', nt-90-nt-70) and the downstream primer 2DS3_PCR_Ex12_R (sequence: 5'-CTCTGACCTGTGACCATGATCAG -3', nt2368 to nt2390), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, The amplified fragment was 2480 bp in length.
  • the second pair of PCR primers include the upstream primer 2DS3_PCR_Ex45_F (sequence: 5'-CTGAGCCCAGCGGCAAGGC-3', nt3586-nt3604) and the downstream primer 2DS3_PCR_Ex45_R (sequence: 5'-ATCCCTCCCTCACACCGAGGA-3', nt6039-nt6059), specific amplification 4
  • the sequence of the exon, the 4th intron, the 5th exon, and part of the 2/3 intron and part of the 5th intron, the amplified fragment of interest is 2474 bp.
  • the third pair of PCR primers includes the upstream primer 2DS3_PCR_Ex6_F (sequence: 5'-TACCAGGGTTCTCCTTTCTCTAG-3', nt7491 to nt7513) and the downstream primer 2DS3_PCR_Ex6_R (sequence: 5'-AGGAAGGGGACCAGGAGCG-3', nt9878 to nt9896), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 2406 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DS3_PCR_Ex789_F (sequence: 5'-TGATGTTGAAGGAAGAGGCTCTT-3', nt10853-nt10875) and the downstream primer 2DS3_PCR_Ex789_R (sequence: 5'-GATAGTCTGAGGGGAGGTGGAACT-3', nt14688-nt14711), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest The length is 3859bp.
  • the first pair of PCR primers that amplify the entire coding region of the KIR2DS4 gene include the upstream primer 2DS4_PCR_Ex12_F (sequence: 5'-ACCATGTCGCTCATGGTCATCAT-3', nt-3 to nt20) and the downstream primer 2DS4_PCR_Ex12_R (sequence: 5'-TTGTCCTGACCACCTTGGGGT-3 ', nt3070 to nt3090), specific amplification of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, the purpose of amplification
  • the fragment length is 3093 bp.
  • the second pair of PCR primers includes the upstream primer 2DS4_PCR_Ex45_F (sequence: 5'-TCAGTTCATACCTCCTGCCAAGG-3', nt4419 ⁇ nt4441) and the downstream primer 2DS4_PCR_Ex45_R (sequence: 5'-CGTGGTCAGGAGTTCCAGAGC-3', nt7611 to nt7631), specific amplification 4
  • the sequence of the exon, the fourth intron, the exon 5, and part of the 2/3 intron and part of the 5th intron, the amplified fragment of interest is 3213 bp in length.
  • the third pair of PCR primers includes the upstream primer 2DS4_PCR_Ex6_F (sequence: 5'-CTGGACTCCCAGGGCCCAATG-3', nt10004 to nt10024) and the downstream primer 2DS4_PCR_Ex6_R (sequence: 5'-AAGGTTTCCACCTCCCCAGGG-3', nt10212 to nt10232), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 229 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DS4_PCR_Ex789_F (sequence: 5'-GAAAGCCCGCTGAATCCTC-3', nt12884-nt12902) and the downstream primer 2DS4_PCR_Ex789_R (sequence: 5'-GCAGAAGGCTGAAAGATAGTCTG-3', nt15726-nt15748), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 2865 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR2DS5 gene includes the upstream primer 2DS5_PCR_Ex12_F (sequence: 5'-TGAGAACAATTTCCAGGAAGCCG-3', nt-199-nt-177) and the downstream primer 2DS5_PCR_Ex12_R (sequence: 5'-CCTTTCCTGTGGACACTTGTC -3', nt2870 ⁇ nt2890), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, The amplified fragment was 3089 bp in length.
  • the second pair of PCR primers includes the upstream primer 2DS5_PCR_Ex45_F (preface Column: 5'-TCCTGCCAAGGATTCCAATTCGA-3', nt3609 ⁇ nt3631) and downstream primer 2DS5_PCR_Ex45_R (sequence: 5'-TCTGTCCATGCTTCTCTCCATCC-3', nt6181 ⁇ nt6203), specifically amplifying the fourth exon, the fourth intron, The 5th exon, and the sequence of part 2/3 intron and part 5 intron, the amplified fragment of interest is 2595 bp.
  • the third pair of PCR primers includes the upstream primer 2DS5_PCR_Ex6_F (sequence: 5'-CTTGAAGTCTCAAGACAGTGGGT-3', nt9083 to nt9105) and the downstream primer 2DS5_PCR_Ex6_R (sequence: 5'-ATGCACTTCATACTTTGAGCTAG-3', nt9923 to nt9945), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 863 bp.
  • the fourth pair of PCR primers includes the upstream primer 2DS5_PCR_Ex789_F (sequence: 5'-TGATGTKGAAGGAAGAGGCTCTG-3', nt11029-nt11051) and the downstream primer 2DS5_PCR_Ex789_R (sequence: 5'-AGGGGAGGTGGAACTGCATGAGA-3', nt14857 ⁇ nt14879), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 3851 bp.
  • the first pair of PCR primers that amplify the entire coding region of the KIR3DL1 gene include the upstream primer 3DL1_PCR_Ex12_F (sequence: 5'-CGAGGTGTCAATTCTAGTGAGAG-3', nt-215-nt-193) and the downstream primer 3DL1_PCR_Ex12_R (sequence: 5'-TACCACAAACATGGCAGCG -3', nt2689 to nt2707), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and a part of the second intron, The amplified fragment was 2922 bp in length.
  • the second pair of PCR primers include the upstream primer 3DL1_PCR_Ex345_F (sequence: 5'-CACCCAGGTGTGGTAGGAGCC-3', nt1700-nt1720) and the downstream primer 3DL1_PCR_Ex345_R (sequence: 5'-CTCTGTGTGGGTGAGAGGCCATG-3', nt5684-nt5706), specific amplification 3
  • the third pair of PCR primers includes the upstream primer 3DL1_PCR_Ex6_F (sequence: 5'-GCCTGTAATACCACTACTCGGGT-3', nt8050 ⁇ nt8072) and downstream primer 3DL1_PCR_Ex6_R (sequence: 5'-CTAAAACACCTCGCCCTCATC-3', nt8921 ⁇ nt8941), specifically amplifying the partial sequence of exon 6 and its flanks, The amplified fragment was 892 bp in length.
  • the fourth pair of PCR primers includes the upstream primer 3DL1_PCR_Ex789_F (sequence: 5'-GCTATAACTGAGAAAGCAGGAGG-3', nt12700-nt12722) and the downstream primer 3DL1_PCR_Ex789_R (sequence: 5'-CTGGAAAATAGTCCGAAGAAAGG-3', nt14173-nt14195), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 1496 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR3DL2 gene includes the upstream primer 3DL2_PCR_Ex12_F (sequence: 5'-TGCAAGGTGGCAATTGTAGTCAC-3', nt-217-nt-195) and the downstream primer 3DL2_PCR_Ex12_R (sequence: 5'-CGACGATAGTGACACTGAAGAGC -3', nt1588 to nt1610), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, The amplified fragment was 1827 bp in length.
  • the second pair of PCR primers includes the upstream primer 3DL2_PCR_Ex345_F (sequence: 5'-CCTCCTCTCTAAGGCAGTGCCTC-3', nt1488 ⁇ nt1510) and the downstream primer 3DL2_PCR_Ex345_R (sequence: 5'-CGGGTTTTCCTCACCTGTGACAG-3', nt5429 ⁇ nt5451), specific amplification 3
  • the third pair of PCR primers include the upstream primer 3DL2_PCR_Ex6_F (sequence: 5'-GACAGGGCACCTCCAAACCCTCT-3', nt5584-nt5606) and the downstream primer 3DL2_PCR_Ex6_R (sequence: 5'-ATTTTAGCCCAGTGACATGCACG-3', nt9282 to nt9304), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 3721 bp.
  • the fourth pair of PCR primers includes the upstream primer 3DL2_PCR_Ex789_F (sequence: 5'-GCAGGAGAAAGCTGGGTCTCC-3', nt15186 to nt15206) and the downstream primer 3DL2_PCR_Ex789_R (sequence: 5'-CTGGTTTTGAGACAGGGCTGTTG-3', nt16262-nt16284), specific amplification of exon 7, intron 7, exon 8, intron, ninth exon
  • the sub-and a part of the 6th intron and part of the 3'-untranslated region are sequenced, and the amplified fragment of interest is 1099 bp in length.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR3DL3 gene includes the upstream primer 3DL3_PCR_Ex12_F (sequence: 5'-ACAACATCCTGTGTGCTGCTGAA-3', nt-63-nt-41) and the downstream primer 3DL3_PCR_Ex12_R (sequence: 5'-GTCAACCCCCTGTGTCGCCTG -3', nt815 to nt835), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, The amplified fragment was 898 bp in length.
  • the second pair of PCR primers include the upstream primer 3DL3_PCR_Ex345_F (sequence: 5'-GGAACCACAGTCATGACCCTGAC-3', nt1156-nt1178) and the downstream primer 3DL3_PCR_Ex345_R (sequence: 5'-AAAGGGTGTAGGCGTTGCTGG-3', nt5608-nt5630), specific amplification third
  • the third pair of PCR primers include the upstream primer 3DL3_PCR_Ex789_F (sequence: 5'-TGAGCCAGTCCCTCAAGGCTC-3', nt9865-nt9885) and the downstream primer 3DL3_PCR_Ex789_R (sequence: 5'-GTTTTACTGCTGACAGAAGGCTG-3', nt12007-nt12029), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest The length is 2165 bp.
  • the first pair of PCR primers for amplifying the entire coding region of the KIR3DS1 gene includes the upstream primer 3DS1_PCR_Ex12_F (sequence: 5'-CGAGGTGTCAATTCTAGTGAGAG-3', nt-215-nt-193) and the downstream primer 3DS1_PCR_Ex12_R (sequence: 5'-CCTGTGACCATGATCACCAT) -3', nt2080 to nt2099), specifically amplifying the sequence of the first exon, the first intron, the second exon, and a part of the 5'-promoter region and part of the second intron, Amplified fragment length It is 2314 bp.
  • the second pair of PCR primers include the upstream primer 3DS1_PCR_Ex345_F (sequence: 5'-CAGCTGACACTTGTTGTAGGGAG-3', nt1634-nt1656) and the downstream primer 3DS1_PCR_Ex345_R (sequence: 5'-AGTGGCATGATCTCGGCTCAG-3', nt6472 to nt6492), specific amplification 3
  • the third pair of PCR primers includes the upstream primer 3DS1_PCR_Ex6_F (sequence: 5'-TGATCCGCCCACCTCCGCT-3', nt7633 ⁇ nt7651) and the downstream primer 3DS1_PCR_Ex6_R (sequence: 5'-GCTGGGAGGTTTGAGCCAACG-3', nt9048-nt9068), specific amplification 6th
  • the partial sequence of the exon and its flanks, the length of the amplified fragment of interest is 1436 bp.
  • the fourth pair of PCR primers includes the upstream primer 3DS1_PCR_Ex789_F (sequence: 5'-GCTATAACTGAGAAAGCAGGAGG-3', nt13101-nt13123) and the downstream primer 3DS1_PCR_Ex789_R (sequence: 5'-GAAGGCTGAAAGCTAGTCTGAGG-3', nt14562-nt14584), specific amplification 7th Exon, 7th intron, 8th exon, 8th intron, ninth exon, and part of the 6th intron and part of the 3'-untranslated region, the amplified fragment of interest
  • the length is 1484 bp.
  • the system composition of the PCR amplification reaction is:
  • the PCR amplification reaction can be simultaneously amplified under the same cycle parameters, and the cycle parameters are:
  • the purification reaction system composition of the PCR amplification product is:
  • the purification reaction system of the PCR amplification product can be purified under the same cycle parameters, and the cycle parameters are:
  • KIR2DL1 first exon forward sequencing primer 2DL1_SBT_Ex1_F (sequence: 5'-CGTGTTCCGCTCTTGAGCG-3', nt-177 ⁇ nt-159), first exon reverse sequencing primer 2DL1_SBT_Ex1_R (sequence: 5'- TCACTCCCTCCCTCTATTG-3', nt50 ⁇ nt68);
  • KIR2DL1 second exon forward sequencing primer 2DL1_SBT_Ex2_F (sequence: 5'-TTCTTGGGTGCAGGTAGGC-3', nt855 ⁇ nt873)
  • second exon reverse sequencing primer 2DL1_SBT_Ex2_R (sequence: 5'-ACCCTGGTCCCCACAGAAC-3', nt1210 ⁇ nt1228);
  • KIR2DL1 fourth exon forward sequencing primer 2DL1_SBT_Ex4_F (sequence: 5'-AAGGGGAAGCCTGACTCAA-3', nt3400 ⁇ nt3418), fourth exon reverse sequencing primer 2DL1_SBT_Ex4_R (sequence: 5'-CCAATTCCTGGATCATTCAC-3', nt3827 ⁇ Nt3846);
  • KIR2DL1 fifth exon forward sequencing primer 2DL1_SBT_Ex5_F (sequence: 5'-GTTCTCAGCTCAGGTGAAG-3', nt5240 ⁇ nt5258), fifth exon reverse sequencing primer 2DL1_SBT_Ex5_R (sequence: 5'-AAACAAGCAGTGGGTCACTTGAC-3', nt5574 ⁇ Nt5596);
  • KIR2DL1 sixth exon forward sequencing primer 2DL1_SBT_Ex6_F (sequence: 5'-TTTCCACTGAGTGGAGGAC-3', nt8698 ⁇ nt8716), sixth exon reverse sequencing primer 2DL1_SBT_Ex6_R (sequence: 5'-TGGAGTTCGGAGATGGTGG-3', nt8920 ⁇ Nt8938);
  • KIR2DL1 seventh exon forward sequencing primer 2DL1_SBT_Ex7_F (sequence: 5'-ATGTGGTTACCTGTCAATC-3', nt12979 ⁇ nt12997), seventh exon reverse sequencing primer 2DL1_SBT_Ex7_R (sequence: 5'-TCCTGCTTCCCCACATGGC-3', nt13207 ⁇ Nt13225);
  • KIR2DL1 eighth exon forward sequencing primer 2DL1_SBT_Ex8_F (sequence: 5'-CTCAGCCACCTATGGTCTC-3', nt13533 ⁇ nt13551)
  • eighth exon reverse sequencing primer 2DL1_SBT_Ex8_R (sequence: 5'-TCTCTGTGTGAAAACGCAG-3', nt13835 ⁇ Nt13853);
  • KIR2DL1 ninth exon forward sequencing primer 2DL1_SBT_Ex9_F (sequence: 5'-ACAGAACAGCGAATAGCGA-3', nt13667 ⁇ nt13685), ninth exon reverse sequencing primer 2DL1_SBT_Ex9_R (sequence: 5'-TAAGATGCAGACTCATGCC-3', nt14060 ⁇ Nt14078).
  • KIR2DL2 first exon forward sequencing primer 2DL2_SBT_Ex1_F (sequence: 5'-AGAGGTTGGATCTGAGACGTC-3', nt-263 ⁇ nt-243), first exon reverse sequencing primer 2DL2_SBT_Ex1_R (sequence: 5'- TCTCCAACTCTGGGCCCCG-3', nt81 ⁇ nt99);
  • KIR2DL2 second exon forward sequencing primer 2DL2_SBT_Ex2_F (sequence: 5'-TTCTTGGGTGCAGGTAGGC-3', nt799 to nt817)
  • second exon reverse sequencing primer 2DL2_SBT_Ex2_R (sequence: 5'-CCCAGTCTAACCCTGGTCC-3', nt1163 to nt1181);
  • KIR2DL2 fourth exon forward sequencing primer 2DL2_SBT_Ex4_F (sequence: 5'-AAGGGGAAGCCTCACTCAT-3', nt3332 ⁇ nt3350), fourth exon reverse sequencing primer 2DL2_SBT_Ex4_R (sequence: 5'-GGCCCCTGTGTCTGTCCTC-3', nt3900 ⁇ Nt3918);
  • KIR2DL2 fifth exon forward sequencing primer 2DL2_SBT_Ex5_F (sequence: 5'-GCTGTGACAAGGAAGATCC-3', nt5179 ⁇ nt5197), fifth exon reverse sequencing primer 2DL2_SBT_Ex5_R (sequence: 5'-AAGCTCCTCAGCTAAGGCT-3', nt5564 ⁇ Nt5582);
  • KIR2DL2 sixth exon forward sequencing primer 2DL2_SBT_Ex6_F (sequence: 5'-ATCCCAGGACTCCCAGGGC-3', nt8669 ⁇ nt8687), sixth exon reverse sequencing primer 2DL2_SBT_Ex6_R (sequence: 5'-GGCGTACAATGTCAGAGCTGC-3', nt8928 ⁇ Nt8948);
  • KIR2DL2 seventh exon forward sequencing primer 2DL2_SBT_Ex7_F (sequence: 5'-ATCTGGGTGCTTGTCCTAA-3', nt12990 ⁇ nt13008), seventh exon reverse sequencing primer 2DL2_SBT_Ex7_R (sequence: 5'-CCTCTGCTTCGTGAGACTTAC-3', nt13213 ⁇ Nt13233);
  • KIR2DL2 eighth exon forward sequencing primer 2DL2_SBT_Ex8_F (sequence: 5'-CCCAGAAGTGCCCTCCGAG-3', nt13628 ⁇ nt13646), eighth exon reverse sequencing primer 2DL2_SBT_Ex8_R (sequence: 5'-TCTCTGTGTGAAAACGCAG-3', nt13876 ⁇ Nt13894);
  • KIR2DL2 ninth exon forward sequencing primer 2DL2_SBT_Ex9_F (sequence: 5'-ACAGAACAGCGAATAGCGA-3', nt13708 ⁇ nt13726), ninth exon reverse sequencing primer 2DL2_SBT_Ex9_R (sequence: 5'-GGCTGTTGTCTCTAGAAGACG-3', nt14026 ⁇ Nt14048).
  • KIR2DL3 first exon forward sequencing primer 2DL3_SBT_Ex1_F (sequence: 5'-CYGMCTGTCTGCACAGA-3', nt-24 to nt-8), first exon reverse sequencing primer 2DL3_SBT_Ex1_R (sequence: 5'- TCTCCAACTCTGGGCCCCG-3', Nt81 ⁇ nt99);
  • KIR2DL3 second exon forward sequencing primer 2DL3_SBT_Ex2_F (sequence: 5'-TTCTTGGGTGCAGGTAGGC-3', nt799 ⁇ nt817)
  • second exon reverse sequencing primer 2DL3_SBT_Ex2_R (sequence: 5'-ACCCTGGTCCCCACAGAAC-3', nt1154 ⁇ Nt1172);
  • KIR2DL3 fourth exon forward sequencing primer 2DL3_SBT_Ex4_F (sequence: 5'-CAGCAAGGGGAAGCCTCA-3', nt3329 ⁇ nt3346), fourth exon reverse sequencing primer 2DL3_SBT_Ex4_R (sequence: 5'-GGCCCCTGTGTCTGTCCTC-3', nt3901 ⁇ Nt3919);
  • KIR2DL3 fifth exon forward sequencing primer 2DL3_SBT_Ex5_F (sequence: 5'-GAGCATTAGGTCATAGAGC-3', nt5131 to nt5149), fifth exon reverse sequencing primer 2DL3_SBT_Ex5_R (sequence: 5'-CTCTCTGCATCTGTCCATGCTTC-3', nt5602 ⁇ Nt5624);
  • KIR2DL3 sixth exon forward sequencing primer 2DL3_SBT_Ex6_F (sequence: 5'-TACTCAGGAGTTTGAGGCC-3', nt8310 ⁇ nt8328), sixth exon reverse sequencing primer 2DL3_SBT_Ex6_R (sequence: 5'-GGCGTACAATGTCAGAGCTGC-3', nt8908 ⁇ Nt8928);
  • KIR2DL3 seventh exon forward sequencing primer 2DL3_SBT_Ex7_F (sequence: 5'-TCTGGGTGCTTGTCCTAAAGG-3', nt12969 ⁇ nt12989), seventh exon reverse sequencing primer 2DL3_SBT_Ex7_R (sequence: 5'-CAGGCAATGGTCTGTGAGC-3', nt13361 ⁇ Nt13379);
  • KIR2DL3 eighth exon forward sequencing primer 2DL3_SBT_Ex8_F (sequence: 5'-CTTCATCGCTGGTGCTG-3', nt13166 ⁇ nt13182), eighth exon reverse sequencing primer 2DL3_SBT_Ex8_R (sequence: 5'-GCTGAGTGAGGGAGGGTGC-3', nt13772 ⁇ Nt13790);
  • KIR2DL3 ninth exon forward sequencing primer 2DL3_SBT_Ex9_F (sequence: 5'-CCCAGCCTCGTGGCTAG-3', nt13724 ⁇ nt13740), ninth exon reverse sequencing primer 2DL3_SBT_Ex9_R (sequence: 5'-GGCAGGAGACAACTTTGGATCW-3', nt13957 ⁇ Nt13978).
  • KIR2DL4 first exon forward sequencing primer 2DL4_SBT_Ex1_F (sequence: 5'-GTGGTCAATGTGTCAACTGCACG-3', nt-99 to nt-77), first exon reverse sequencing primer 2DL4_SBT_Ex1_R (sequence: 5'-CCTGAGCCACTGGGCGCCA-3', nt 166 to nt 184);
  • KIR2DL4 second exon forward sequencing primer 2DL4_SBT_Ex2_F (sequence: 5'-GAGCCATGTTCTGAAGCAAGT-3', nt111 ⁇ nt131), second exon reverse sequencing primer 2DL4_SBT_Ex2_R (sequence: 5'-CACCCTCTGTGCTGCCTCC-3', nt345 ⁇ Nt363);
  • KIR2DL4 third exon forward sequencing primer 2DL4_SBT_Ex3_F (sequence: 5'-TACTCCTCTCTGAGGCGGC-3', nt1140 ⁇ nt1158)
  • third exon reverse sequencing primer 2DL4_SBT_Ex3_R (sequence: 5'-CCAGAAGCTCTGGGACTCA-3', nt1502 ⁇ Nt1520);
  • KIR2DL4 fifth exon forward sequencing primer 2DL4_SBT_Ex5_F (sequence: 5'-GGGAGGGGAGCTGTGACAA-3', nt2275 ⁇ nt2293), fifth exon reverse sequencing primer 2DL4_SBT_Ex5_R (sequence: 5'-GCTTCTCTCCATCATCAGC-3', nt2691 ⁇ Nt2709);
  • KIR2DL4 sixth exon forward sequencing primer 2DL4_SBT_Ex6_F (sequence: 5'-CAGGCATCCTCATTGCCAC-3', nt5179 ⁇ nt5197), sixth exon reverse sequencing primer 2DL4_SBT_Ex6_R (sequence: 5'-TGGCAGGTGCTGAGCCAAC-3', nt5341 ⁇ Nt5359);
  • KIR2DL4 seventh exon forward sequencing primer 2DL4_SBT_Ex7_F (sequence: 5'-TCGCCAGACACCTGCATGC-3', nt9519 ⁇ nt9537), seventh exon reverse sequencing primer 2DL4_SBT_Ex7_R (sequence: 5'-TTTGGAGCACCAGC-3', nt9600 ⁇ Nt9613);
  • KIR2DL4 eighth exon forward sequencing primer 2DL4_SBT_Ex8_F (sequence: 5'-GAGGACCCAGAAGTGCCCT-3', nt10030 ⁇ nt10048), eighth exon reverse sequencing primer 2DL4_SBT_Ex8_R (sequence: 5'-CTGGAGAGAGGGAAATCCT-3', nt10215 ⁇ Nt10233);
  • KIR2DL4 ninth exon forward sequencing primer 2DL4_SBT_Ex9_F (sequence: 5'-CCAGCCTCATGGATACAGTCT-3', nt10150 ⁇ nt10170), ninth exon reverse sequencing primer 2DL4_SBT_Ex9_R (sequence: 5'-GGAAGAGTGATGCTCTAAGATGG-3', nt10516 to nt10538).
  • KIR2DL5 first exon forward sequencing primer 2DL5_SBT_Ex1_F (sequence: 5'-CCAAATAACATCCTGTGCGCT-3', nt-67 to nt-47), first exon reverse sequencing primer 2DL5_SBT_Ex1_R (sequence: 5'- AGATCTCCATCCCCGCACT-3', nt64 ⁇ nt82);
  • KIR2DL5 second exon forward sequencing primer 2DL5_SBT_Ex2_F (sequence: 5'-CAGCAAGGGCCTGGCTACC-3', nt668-nt686)
  • second exon reverse sequencing primer 2DL5_SBT_Ex2_R (sequence: 5'-GAAAATCCCCCACCGGGCT-3', nt872 ⁇ Nt890);
  • KIR2DL5 third exon forward sequencing primer 2DL5_SBT_Ex3_F (sequence: 5'-ACAAGCCCTTGCTGTCTGCCT-3', nt1575 ⁇ nt1595)
  • third exon reverse sequencing primer 2DL5_SBT_Ex3_R (sequence: 5'-CAGATGCTCTGGGATTCAG-3', nt1891 ⁇ Nt1909);
  • KIR2DL5 fifth exon forward sequencing primer 2DL5_SBT_Ex5_F (sequence: 5'-CAGGTGTGAGGGGAGCTGT-3', nt2665 ⁇ nt2683), fifth exon reverse sequencing primer 2DL5_SBT_Ex5_R (sequence: 5'-CGGGTCTGACCACTCATAGGGT-3', nt2970 ⁇ Nt2991);
  • KIR2DL5 sixth exon forward sequencing primer 2DL5_SBT_Ex6_F (sequence: 5'-TCACCTCTCTCCTGTCCTGTGT-3', nt5165 ⁇ nt5186), sixth exon reverse sequencing primer 2DL5_SBT_Ex6_R (sequence: 5'-TGAGCCAATGCTTGAATCCAAGA-3', nt5295 ⁇ Nt5317);
  • KIR2DL5 seventh exon forward sequencing primer 2DL5_SBT_Ex7_F (sequence: 5'-ATCCATAAAGAGGAACTGCTATA-3', nt7951 ⁇ nt7973), seventh exon reverse sequencing primer 2DL5_SBT_Ex7_R (sequence: 5'-CCTTGGTCCAGGGACCATC-3', nt8201 ⁇ Nt8219);
  • KIR2DL5 eighth exon forward sequencing primer 2DL5_SBT_Ex8_F (sequence: 5'-CACCTACGGCCTCCCGCTG-3', nt8480 ⁇ nt8498), eighth exon reverse sequencing primer 2DL5_SBT_Ex8_R (sequence: 5'-GAGGGTGCTCACATTCTTCAA-3', nt8680 ⁇ Nt8700);
  • KIR2DL5 ninth exon forward sequencing primer 2DL5_SBT_Ex9_F (sequence: 5'-TGCCGGGGACAGAACAGTG-3', nt8600 to nt8618), ninth exon reverse sequencing primer 2DL5_SBT_Ex9_R (sequence: 5'-CTCAAGGCCTGACTGTGGTGCTT-3', nt8899 to nt8921).
  • KIR2DS1 first exon forward sequencing primer 2DS1_SBT_Ex1_F (sequence: 5'-CTCCCATGATGTGGTCAAC-3', nt-109 ⁇ nt-91), first exon reverse sequencing primer 2DS1_SBT_Ex1_R (sequence: 5'- TCTCCAACCCCACACTCCC-3', nt61 ⁇ nt79);
  • KIR2DS1 second exon forward sequencing primer 2DS1_SBT_Ex2_F (sequence: 5'-TTCTTGGGTGCAGGTAGGC-3', nt855 ⁇ nt873)
  • second exon reverse sequencing primer 2DS1_SBT_Ex2_R (sequence: 5'-CTGCCAAGGGAATGAAAGG-3', nt1185 ⁇ Nt1203);
  • KIR2DS1 fourth exon forward sequencing primer 2DS1_SBT_Ex4_F (sequence: 5'-GGTGCCATGGATGGGATGA-3', nt3423 ⁇ nt3441), fourth exon reverse sequencing primer 2DS1_SBT_Ex4_R (sequence: 5'-CAAGTCCTGGATCATTCAC-3', nt3827 ⁇ Nt3845);
  • KIR2DS1 fifth exon forward sequencing primer 2DS1_SBT_Ex5_F (sequence: 5'-AGAGCAGGGGAGTGAGTTC-3', nt5221 ⁇ nt5239), fifth exon reverse sequencing primer 2DS1_SBT_Ex5_R (sequence: 5'-GGCTCTAGGATCATAGGAC-3', nt5628 ⁇ Nt5646);
  • KIR2DS1 sixth exon forward sequencing primer 2DS1_SBT_Ex6_F (sequence: 5'-TCCTCAAAGATTTCCACTGAGTG-3', nt8684 ⁇ nt8706), sixth exon reverse sequencing primer 2DS1_SBT_Ex6_R (sequence: 5'-GTGAGATGCTGAGTCAACGC-3', nt8871 ⁇ Nt8890);
  • KIR2DS1 seventh exon forward sequencing primer 2DS1_SBT_Ex7_F (sequence: 5'-GTGGTTACCTGCCAATCAAG-3', nt12981 ⁇ nt13000), seventh exon reverse sequencing primer 2DS1_SBT_Ex7_R (sequence: 5'-TGAGGAACACACATCCGCGT-3', nt13236 ⁇ Nt13255);
  • KIR2DS1 eighth exon forward sequencing primer 2DS1_SBT_Ex8_F (sequence: 5'-ATGGCCTCCCCCTGTTTGT-3', nt13547 ⁇ nt13565)
  • eighth exon reverse sequencing primer 2DS1_SBT_Ex8_R (sequence: 5'-GGGAATAAGACTAGCCACG-3', nt13713 ⁇ nt13731);
  • KIR2DS1 ninth exon forward sequencing primer 2DS1_SBT_Ex9_F (sequence: 5'-CTCCTCGGCCCAGCCTCGT-3', nt13697 ⁇ nt13715), ninth exon reverse sequencing primer 2DS1_SBT_Ex9_R (sequence: 5'-TCCCCTCAAGGCCTGACTG-3', nt13971 ⁇ Nt13989).
  • KIR2DS2 first exon forward sequencing primer 2DS2_SBT_Ex1_F (sequence: 5'-ATAACATCCTGTGCGCTGC-3', nt-63 ⁇ nt-45), first exon reverse sequencing primer 2DS2_SBT_Ex1_R (sequence: 5'- CCAACTCTGGGCCCCGATC-3', nt78 ⁇ nt96);
  • KIR2DS2 second exon forward sequencing primer 2DS2_SBT_Ex2_F (sequence: 5'-AAGGGAGTCCTGGTTTGCC-3', nt772 ⁇ nt790), second exon reverse sequencing primer 2DS2_SBT_Ex2_R (sequence: 5'-GTCAGAAATGTGGGCCGAG-3', nt981 ⁇ Nt999);
  • KIR2DS2 fourth exon forward sequencing primer 2DS2_SBT_Ex4_F (sequence: 5'-CACCTTCTAAACTCACAACC-3', nt3268 ⁇ nt3287)
  • fourth exon reverse sequencing primer 2DS2_SBT_Ex4_R (sequence: 5'-CACTCTGCAGCCCAATGAC-3', nt3624 ⁇ Nt3642);
  • KIR2DS2 fifth exon forward sequencing primer 2DS2_SBT_Ex5_F (sequence: 5'-AGAGCAGGGGAGTGAGTTC-3', nt5030 ⁇ nt5048), fifth exon reverse sequencing primer 2DS2_SBT_Ex5_R (sequence: 5'-GAAGCTCCTCAGCTAAGGC-3', nt5453 ⁇ Nt5471);
  • KIR2DS2 sixth exon forward sequencing primer 2DS2_SBT_Ex6_F (sequence: 5'-CCAGGGCCCAATATTAGAT-3', nt8465 ⁇ nt8483), sixth exon reverse sequencing primer 2DS2_SBT_Ex6_R (sequence: 5'-TGAGTCAACGCCTGAATCC-3', nt8686 ⁇ Nt8704);
  • KIR2DS2 seventh exon forward sequencing primer 2DS2_SBT_Ex7_F (sequence: 5'-GCCAATCAAGAAATGCGAG-3', nt12815 ⁇ nt12833)
  • seventh exon reverse sequencing primer 2DS2_SBT_Ex7_R (sequence: 5'-GTCCTGCCTCTGTGGCTCC-3', nt13108 ⁇ Nt13126);
  • KIR2DS2 eighth exon forward sequencing primer 2DS2_SBT_Ex8_F (sequence: 5'-ATGAGGACCCAGAAGTGCC-3', nt13407-nt13425), eighth exon reverse sequencing primer 2DS2_SBT_Ex8_R (sequence: 5'-CCTCCTGATGGTCTTGTTC-3', nt13621 to nt13639);
  • KIR2DS2 ninth exon forward sequencing primer 2DS2_SBT_Ex9_F (sequence: 5'-AGGTAGGTGCTCCTCGGCC-3', nt13512 ⁇ nt13530), ninth exon reverse sequencing primer 2DS2_SBT_Ex9_R (sequence: 5'-AGAAGATCCCCTCAAGGCC-3', nt13801 ⁇ Nt13819).
  • KIR2DS3 first exon forward sequencing primer 2DS3_SBT_Ex1_F (sequence: 5'-CAGGGAGCCAAATAACATC-3', nt-75 ⁇ nt-57), first exon reverse sequencing primer 2DS3_SBT_Ex1_R (sequence: 5'- CGCTCCCTCCCTCTATTCC-3', nt49 ⁇ nt67);
  • KIR2DS3 second exon forward sequencing primer 2DS3_SBT_Ex2_F (sequence: 5'-GCCGAGAGCCCTGTTCTTG-3', nt1182 ⁇ nt1200), second exon reverse sequencing primer 2DS3_SBT_Ex2_R (sequence: 5'-ACAGGACTTCCCTCCCGTT-3', nt1432 ⁇ Nt1450);
  • KIR2DS3 fourth exon forward sequencing primer 2DS3_SBT_Ex4_F (sequence: 5'-AGAGAGACACCTTCTAAAT-3', nt3780 ⁇ nt3798), fourth exon reverse sequencing primer 2DS3_SBT_Ex4_R (sequence: 5'-ATCATTCACTCTGTGTCCG-3', nt4152 ⁇ Nt4170);
  • KIR2DS3 fifth exon forward sequencing primer 2DS3_SBT_Ex5_F (sequence: 5'-AGGAAGATCCTCCATAAGG-3', nt5596 ⁇ nt5614), fifth exon reverse sequencing primer 2DS3_SBT_Ex5_R (sequence: 5'-GGCTCTAGGATCATAGGAC-3', nt5957 ⁇ Nt5975);
  • KIR2DS3 sixth exon forward sequencing primer 2DS3_SBT_Ex6_F (sequence: 5'-TCCCAGGGCCCAATATTAG-3', nt8968 ⁇ nt8986), sixth exon reverse sequencing primer 2DS3_SBT_Ex6_R (sequence: 5'-CACTGAGCCCTGTGTTGGG-3', nt9291 ⁇ Nt9309);
  • KIR2DS3 seventh exon forward sequencing primer 2DS3_SBT_Ex7_F (sequence: 5'-GTGCTTGTCCTAAAGAGACGT-3', nt13284 ⁇ nt13304), seventh exon reverse sequencing primer 2DS3_SBT_Ex7_R (sequence: 5'-TGAGTGGCTGCAGGGGACG-3', nt13709 ⁇ nt13727);
  • KIR2DS3 eighth exon forward sequencing primer 2DS3_SBT_Ex8_F (sequence: 5'-GACCTCAGGCACCTATGGC-3', nt13862 ⁇ nt13880), eighth exon reverse sequencing primer 2DS3_SBT_Ex8_R (sequence: 5'-GCTGAGTGAGGGAGGGTGC-3', nt14082 ⁇ Nt14100);
  • KIR2DS3 ninth exon forward sequencing primer 2DS3_SBT_Ex9_F (sequence: 5'-CGGCCCAGCCTCGTGGCTA-3', nt14031 ⁇ nt14049), ninth exon reverse sequencing primer 2DS3_SBT_Ex9_R (sequence: 5'-TGTCTTGGGCCTCTGAGAAGGGG-3', nt14196 ⁇ Nt14218).
  • KIR2DS4 first exon forward sequencing primer 2DS4_SBT_Ex1_F (sequence: 5'-ACCATGTCGCTCATGGTC-3', nt-3 to nt15), first exon reverse sequencing primer 2DS4_SBT_Ex1_R (sequence: 5'-GGCTCATCACTCCATCTCT- 3', nt148 ⁇ nt166);
  • KIR2DS4 second exon forward sequencing primer 2DS4_SBT_Ex2_F (sequence: 5'-GAAGGGGCTGGCTATCAAG-3', nt2218 ⁇ nt2236), second exon reverse sequencing primer 2DS4_SBT_Ex2_R (sequence: 5'-GACTTCCCTCCCGTTTCAG-3', nt2404 ⁇ Nt2422);
  • KIR2DS4 fourth exon forward sequencing primer 2DS4_SBT_Ex4_F (sequence: 5'-AGAGAGACACCTTCTAAAC-3', nt4774 ⁇ nt4792), fourth exon reverse sequencing primer 2DS4_SBT_Ex4_R (sequence: 5'-CACCTGGGTCTCCAAGTCC-3', nt5168 ⁇ Nt5186);
  • KIR2DS4 fifth exon forward sequencing primer 2DS4_SBT_Ex5_F (sequence: 5'-AGTTCTCAGGTCAGGTGTG-3', nt6589 ⁇ nt6607)
  • fifth exon reverse sequencing primer 2DS4_SBT_Ex5_R (sequence: 5'-GGAAGCTCCTCAGCTAAGG-3', nt7001 ⁇ Nt7019);
  • KIR2DS4 sixth exon forward sequencing primer 2DS4_SBT_Ex6_F (sequence: 5'-CTGGACTCCCAGGGCCCAATG-3', nt10004 ⁇ nt10024), sixth exon reverse sequencing primer 2DS4_SBT_Ex6_R (sequence: 5'-TTCCACCTCCCCAGGGTTC-3', nt10209 ⁇ Nt10227);
  • KIR2DS4 seventh exon forward sequencing primer 2DS4_SBT_Ex7_F (sequence: 5'-CGCCATTTGGGTGCTTGTC-3', nt14317 to nt14335), seventh exon reverse sequencing primer 2DS4_SBT_Ex7_R (sequence: 5'-GGTGAGGAACACACATCCG-3', nt14611 to nt14629);
  • KIR2DS4 eighth exon forward sequencing primer 2DS4_SBT_Ex8_F (sequence: 5'-AGTCTGCTGTTGGCAACTG-3', nt14883 ⁇ nt14901), eighth exon reverse sequencing primer 2DS4_SBT_Ex8_R (sequence: 5'-CCTCCTGATGGTCTTGTTC-3', nt15169 ⁇ Nt15187);
  • KIR2DS4 ninth exon forward sequencing primer 2DS4_SBT_Ex9_F (sequence: 5'-CTCGGCCCAGCCTCGTGGC-3', nt15072 ⁇ nt15090), ninth exon reverse sequencing primer 2DS4_SBT_Ex9_R (sequence: 5'-CAACTTTGGATCTGGGCTC-3', nt15304 ⁇ Nt15322).
  • KIR2DS5 first exon forward sequencing primer 2DS5_SBT_Ex1_F (sequence: 5'-GGCGCCAAATAACATCCTG-3', nt-72-nt-54), first exon reverse sequencing primer 2DS5_SBT_Ex1_R (sequence: 5'- GCCCAGATCTCCATCCCCG-3', nt68 ⁇ nt86);
  • KIR2DS5 second exon forward sequencing primer 2DS5_SBT_Ex2_F (sequence: 5'-GGCACTGAGKGTGAGTTTC-3', nt1383 ⁇ nt1401)
  • second exon reverse sequencing primer 2DS5_SBT_Ex2_R (sequence: 5'-TGACAGGACTTCCCTCCCG-3', nt1606 ⁇ Nt1624);
  • KIR2DS5 fourth exon forward sequencing primer 2DS5_SBT_Ex4_F (sequence: 5'-GACACCTTCTAAATTCACAAAC-3', nt3958 ⁇ nt3979), fourth exon reverse sequencing primer 2DS5_SBT_Ex4_R (sequence: 5'-CTCTGCATCCCAATGACAATG-3', nt4315 ⁇ Nt4335);
  • KIR2DS5 fifth exon forward sequencing primer 2DS5_SBT_Ex5_F (sequence: 5'-CCTCCCTGAGGAAAATGCC-3', nt5786 ⁇ nt5804), fifth exon reverse sequencing primer 2DS5_SBT_Ex5_R (sequence: 5'-TCATAGGACATGGGACAGC-3', nt6129 ⁇ Nt6147);
  • KIR2DS5 sixth exon forward sequencing primer 2DS5_SBT_Ex6_F (sequence: 5'-CAGGGCCCAATATTAGATAAC-3', nt9147 ⁇ nt9167), sixth exon reverse sequencing primer 2DS5_SBT_Ex6_R (sequence: 5'-GGAGTATCTGGAGTTCGGAGA-3', nt9426 to nt9446);
  • KIR2DS5 seventh exon forward sequencing primer 2DS5_SBT_Ex7_F (sequence: 5'-CTGTCAATCAAGAAATGCGAG-3', nt13495 ⁇ nt13515)
  • seventh exon reverse sequencing primer 2DS5_SBT_Ex7_R (sequence: 5'-GGAACACACCCCCGTGC-3', nt13740 ⁇ Nt13758);
  • KIR2DS5 eighth exon forward sequencing primer 2DS5_SBT_Ex8_F (sequence: 5'-AGATAGAATGTCTGAGTCTGC-3', nt14003 ⁇ nt14023), eighth exon reverse sequencing primer 2DS5_SBT_Ex8_R (sequence: 5'-ACACAGTGATCCAATTATGCG-3', nt14329 ⁇ Nt14349);
  • KIR2DS5 ninth exon forward sequencing primer 2DS5_SBT_Ex9_F (sequence: 5'-GGTAGGTGCTCCTCGGCCC-3', nt14195 ⁇ nt14213), ninth exon reverse sequencing primer 2DS5_SBT_Ex9_R (sequence: 5'-ATGGGAGCTGGCAACCCGG-3', nt14528 ⁇ Nt14546).
  • KIR3DL1 first exon forward sequencing primer 3DL1_SBT_Ex1_F (sequence: 5'-CAGGGCGCCAAATAACATC-3', nt-74 to nt-56), first exon reverse sequencing primer 3DL1_SBT_Ex1_R (sequence: 5'- CAGATCTCCATCCCCGCAC-3', nt65 ⁇ nt83);
  • KIR3DL1 second exon forward sequencing primer 3DL1_SBT_Ex2_F (sequence: 5'-AGGGCCTGGCTGCCAAGAC-3', nt940 ⁇ nt958)
  • second exon reverse sequencing primer 3DL1_SBT_Ex2_R (sequence: 5'-AATGTGGGCCGAGCATCCG-3', nt1182 ⁇ Nt1200);
  • KIR3DL1 third exon forward sequencing primer 3DL1_SBT_Ex3_F (sequence: 5'-GGGGAGAATCTTCTGGGCACT-3', nt1736 ⁇ nt1756), third exon reverse sequencing primer 3DL1_SBT_Ex3_R (sequence: 5'-TGATGGGACCCTGACGGAC-3', nt2167 ⁇ Nt2185);
  • KIR3DL1 fourth exon forward sequencing primer 3DL1_SBT_Ex4_F (sequence: 5'-TGGAGGCACCTGCACCAGG-3', nt3052 ⁇ nt3070), fourth exon reverse sequencing primer 3DL1_SBT_Ex4_R (sequence: 5'-TGGTACAGACCTCACCAAG-3', nt3633 ⁇ Nt3651);
  • KIR3DL1 fifth exon forward sequencing primer 3DL1_SBT_Ex5_F (sequence: 5'-CAGGTATGAGGGGAGCTATG-3', nt5001 to nt5020), fifth exon reverse sequencing primer 3DL1_SBT_Ex5_R (sequence: 5'-CCTGTCTGCCATCCTGCGC-3', nt5490 to nt5508);
  • KIR3DL1 sixth exon forward sequencing primer 3DL1_SBT_Ex6_F (sequence: 5'-AAGCACCCTCATTTCCTCAC-3', nt8485 ⁇ nt8504)
  • sixth exon reverse sequencing primer 3DL1_SBT_Ex6_R (sequence: 5'-CAACACTTGCATCCAAGGC-3', nt8631 ⁇ Nt8649);
  • KIR3DL1 seventh exon forward sequencing primer 3DL1_SBT_Ex7_F (sequence: 5'-CCCGCCATCTGGGTGCTTG-3', nt12734 ⁇ nt12752), seventh exon reverse sequencing primer 3DL1_SBT_Ex7_R (sequence: 5'-TCCTGCTTCCCCACATGGC-3', nt13001 ⁇ Nt13019);
  • KIR3DL1 eighth exon forward sequencing primer 3DL1_SBT_Ex8_F (sequence: 5'-CCAGAAGTGCCCTCCGAGC-3', nt13382 ⁇ nt13400), eighth exon reverse sequencing primer 3DL1_SBT_Ex8_R (sequence: 5'-TGTTTGGGAATAACACTAGCC-3', nt13507 ⁇ Nt13527);
  • KIR3DL1 ninth exon forward sequencing primer 3DL1_SBT_Ex9_F (sequence: 5'-CGTGGCTAGTGTTATTCCC-3', nt13504 ⁇ nt13522)
  • ninth exon reverse sequencing primer 3DL1_SBT_Ex9_R (sequence: 5'-ATGGGAGCTGGCAACTCGG-3', nt13833 ⁇ Nt13851).
  • KIR3DL2 first exon forward sequencing primer 3DL2_SBT_Ex1_F (sequence: 5'-GCCAAATAACATCCTGTGCGC-3', nt-68-nt-48), first exon reverse sequencing primer 3DL2_SBT_Ex1_R (sequence: 5'- TAGGCCGAGATCTCCATCC-3', nt71 ⁇ nt89);
  • KIR3DL2 second exon forward sequencing primer 3DL2_SBT_Ex2_F (sequence: 5'-GAGGCTAAGTTTACCTTCAGC-3', nt624 ⁇ nt644)
  • second exon reverse sequencing primer 3DL2_SBT_Ex2_R (sequence: 5'-GACTTCCCTCCTGTTTCAG-3', nt834 ⁇ Nt852);
  • KIR3DL2 third exon forward sequencing primer 3DL2_SBT_Ex3_F (sequence: 5'-GGCCCAGCACTGTGGTGCC-3', nt1553 ⁇ nt1571)
  • third exon reverse sequencing primer 3DL2_SBT_Ex3_R (sequence: 5'-GCCCATTTCCCCTGTATTC-3', nt1930 ⁇ nt1948);
  • KIR3DL2 fourth exon forward sequencing primer 3DL2_SBT_Ex4_F (sequence: 5'-GAGAGATGCCTTCTAAACT-3', nt3235 ⁇ nt3253), fourth exon reverse sequencing primer 3DL2_SBT_Ex4_R (sequence: 5'-TCTCCATAAGAATCCCACGCT-3', nt3663 ⁇ Nt3683);
  • KIR3DL2 fifth exon forward sequencing primer 3DL2_SBT_Ex5_F (sequence: 5'-CCTCCCTGAGGAAACTGCC-3', nt5111 ⁇ nt5129)
  • fifth exon reverse sequencing primer 3DL2_SBT_Ex5_R (sequence: 5'-GAAAGAGCCGAAGCATCTG-3', nt5361 ⁇ Nt5379);
  • KIR3DL2 sixth exon forward sequencing primer 3DL2_SBT_Ex6_F (sequence: 5'-CAACCTCAAAGATTTCCATTG-3', nt8530 ⁇ nt8550), sixth exon reverse sequencing primer 3DL2_SBT_Ex6_R (sequence: 5'-CAACACTTGCATCCAAGGC-3', nt8707 ⁇ Nt8725);
  • KIR3DL2 seventh exon forward sequencing primer 3DL2_SBT_Ex7_F (sequence: 5'-GAGATGTTCCATGTGGTTACC-3', nt15231 ⁇ nt15251), seventh exon reverse sequencing primer 3DL2_SBT_Ex7_R (sequence: 5'-GGAACACACCCCCGTGC-3', nt15494 ⁇ Nt15512);
  • KIR3DL2 eighth exon forward sequencing primer 3DL2_SBT_Ex8_F (sequence: 5'-TCTGAGTCTGGATGTTGGC-3', nt15764 ⁇ nt15782), eighth exon reverse sequencing primer 3DL2_SBT_Ex8_R (sequence: 5'-GGGTCTTGTTCATCAGAGTCC-3', nt16046 ⁇ Nt16066);
  • KIR3DL2 ninth exon forward sequencing primer 3DL2_SBT_Ex9_F (sequence: 5'-CCTCGGCCCAGCCTCACGG-3', nt15957-nt15975), ninth exon reverse sequencing primer 3DL2_SBT_Ex9_R (sequence: 5'-GACTGTGGTGCTCGTGGGC-3', nt16216 ⁇ Nt16234).
  • KIR3DL3 first exon forward sequencing primer 3DL3_SBT_Ex1_F (sequence: 5'-ACAACATCCTGTGTGCTGCTGAA-3', nt-63-nt-41), first exon reverse sequencing primer 3DL3_SBT_Ex1_R (sequence: 5'- TCCCTCCCTCGATTCCCTT-3', nt46 ⁇ nt64);
  • KIR3DL3 second exon forward sequencing primer 3DL3_SBT_Ex2_F (sequence: 5'-GATGTACAGATGGATCATC-3', nt672 to nt690), second exon reverse sequencing primer 3DL3_SBT_Ex2_R (sequence: 5'-GTCAACCCCCTGTGTCGCCTG-3', nt815 to nt835);
  • KIR3DL3 third exon forward sequencing primer 3DL3_SBT_Ex3_F (sequence: 5'-GCTCCACATCCTCCTCTCT-3', nt1474 ⁇ nt1492)
  • third exon reverse sequencing primer 3DL3_SBT_Ex3_R (sequence: 5'-ATCCCCCTTTACCCCAAAT-3', nt1905 ⁇ Nt1923);
  • KIR3DL3 fourth exon forward sequencing primer 3DL3_SBT_Ex4_F (sequence: 5'-GGGAAGCCTCACTTATTTCAG-3', nt2996 ⁇ nt3016), fourth exon reverse sequencing primer 3DL3_SBT_Ex4_R (sequence: 5'-ACCTGGGGCTTCCAGTCCT-3', nt3431 ⁇ Nt3449);
  • KIR3DL3 fifth exon forward sequencing primer 3DL3_SBT_Ex5_F (sequence: 5'-GAGAGCTGTGACAASGAAG-3', nt4900 ⁇ nt4918), fifth exon reverse sequencing primer 3DL3_SBT_Ex5_R (sequence: 5'-GCAGGAAGCTCCTCAGCTA-3', nt5294 ⁇ Nt5312);
  • KIR3DL3 seventh exon forward sequencing primer 3DL3_SBT_Ex7_F (sequence: 5'-GTGAGACAATTCATATAGA-3', nt10650 ⁇ nt10668), seventh exon reverse sequencing primer 3DL3_SBT_Ex7_R (sequence: 5'-TGCTTCCCCACATGGCCCT-3', nt10852 ⁇ Nt10870);
  • KIR3DL3 eighth exon forward sequencing primer 3DL3_SBT_Ex8_F (sequence: 5'-GACCTCAGGCACCTATGGC-3', nt11178 ⁇ nt11196), eighth exon reverse sequencing primer 3DL3_SBT_Ex8_R (sequence: 5'-GAGTGAGGGAGGGTGCTCA-3', nt11395 ⁇ Nt11413);
  • KIR3DL3 ninth exon forward sequencing primer 3DL3_SBT_Ex9_F (sequence: 5'-CRTGGCTAGTCTTATTCCC-3', nt11358 ⁇ nt11376), ninth exon reverse sequencing primer 3DL3_SBT_Ex9_R (sequence: 5'-CCCTAGAAGATCCCATCAA-3', nt11627 ⁇ Nt11645).
  • KIR3DS1 first exon forward sequencing primer 3DS1_SBT_Ex1_F (sequence: 5'-AAGCCATGCTCCGCTCTTG-3', nt-181 to nt-163)
  • first exon reverse sequencing primer 3DS1_SBT_Ex1_R (sequence: 5'-CAGATCTCCATCCCCGCAC-3', nt65 to nt83);
  • KIR3DS1 second exon forward sequencing primer 3DS1_SBT_Ex2_F (sequence: 5'-AGTGGGGGCAGCAGGGTG-3', nt968 ⁇ nt985)
  • second exon reverse sequencing primer 3DS1_SBT_Ex2_R (sequence: 5'-AATGTGGGCCGAGCATCCG-3', nt1182 ⁇ Nt1200);
  • KIR3DS1 third exon forward sequencing primer 3DS1_SBT_Ex3_F (sequence: 5'-GGGGAGAATCTTCTGGGCACT-3', nt1735 ⁇ nt1755), third exon reverse sequencing primer 3DS1_SBT_Ex3_R (sequence: 5'-TGATGGGACCCTGACGGAC-3', nt2166 ⁇ Nt2184);
  • KIR3DS1 fourth exon forward sequencing primer 3DS1_SBT_Ex4_F (sequence: 5'-GGAGAGAGACAGACACGGG-3', nt3485 ⁇ nt3503)
  • fourth exon reverse sequencing primer 3DS1_SBT_Ex4_R (sequence: 5'-TGGTACAGACCTCACCAAG-3', nt4007 ⁇ Nt4025);
  • KIR3DS1 fifth exon forward sequencing primer 3DS1_SBT_Ex5_F (sequence: 5'-CAGGTGTGAGGGGAGCTGT-3', nt5403 ⁇ nt5421), fifth exon reverse sequencing primer 3DS1_SBT_Ex5_R (sequence: 5'-CCTGTCTGCCATCCTGCGC-3', nt5892 ⁇ Nt5910);
  • KIR3DS1 sixth exon forward sequencing primer 3DS1_SBT_Ex6_F (sequence: 5'-TCAAGACAGTGGGCATCGCAC-3', nt8763 ⁇ nt8783), sixth exon reverse sequencing primer 3DS1_SBT_Ex6_R (sequence: 5'-GGGAGGTTTGAGCCAACGCTT-3', nt9045 ⁇ Nt9065);
  • KIR3DS1 seventh exon forward sequencing primer 3DS1_SBT_Ex7_F (sequence: 5'-CGCTGTATGTGGTTACCTGTG-3', nt13165 ⁇ nt13185), seventh exon reverse sequencing primer 3DS1_SBT_Ex7_R (sequence: 5'-GGTGAGGAACACACCCG-3', nt13432 ⁇ Nt13450);
  • KIR3DS1 eighth exon forward sequencing primer 3DS1_SBT_Ex8_F (sequence: 5'-CCAGAAGTGCCCTCCGAGC-3', nt13784 ⁇ nt13802), eighth exon reverse sequencing primer 3DS1_SBT_Ex8_R (sequence: 5'-GCTGAGTGAGGGAGGGTGC-3', nt13944 ⁇ Nt13962);
  • KIR3DS1 ninth exon forward sequencing primer 3DS1_SBT_Ex9_F (sequence: 5'-CGTGGCTAGTGTTATTCCC-3', nt13904 to nt13922), ninth exon reverse sequencing primer 3DS1_SBT_Ex9_R (sequence: 5'-GGCCTCTGAGAAGGGCGAG-3', nt14055 to nt14073).
  • the sequencing reaction composition is:
  • the cycle parameters of the sequencing reaction are:
  • the invention develops a scientific and efficient KIR gene PCR amplification strategy based on the structural characteristics of the full-length sequence of the KIR gene, the polymorphism distribution of SNPs and the length of the intron of the exon.
  • KIR gene-specific PCR primers and sequencing primers By designing KIR gene-specific PCR primers and sequencing primers, exploring optimal PCR amplification and sequencing reaction conditions, and researching and establishing all 14 functional KIR genes in the KIR gene family, simultaneous sequencing and typing techniques are suitable for KIR high resolution. Horizontal genotyping, population genetics, bone marrow transplantation tissue matching, disease association research and other fields.
  • the contribution of the present invention is that for the first time, a method for simultaneous sequencing of 14 functional KIR genes suitable for high-pass quantification and high resolution levels has been established.
  • KIR gene According to the structural characteristics of KIR gene, a scientific PCR amplification strategy was developed, and KIR gene-specific PCR primers with similar annealing temperatures were designed, which can be simultaneously amplified under the same PCR amplification conditions, and the time required is short. Time and effort; due to the specificity of PCR primers, the cause was solved Non-specific amplification problems with highly homologous KIR sequences.
  • the amplification product can directly identify the presence or absence of the KIR gene by electrophoresis, and does not need to be detected by a commercial KIR-SSP kit.
  • This method can sequence all the exons of each functional KIR gene, solve the deficiencies in the KIR sequencing typing method reported by previous researchers, and the obtained sequence has no background signal and peak, which is easy.
  • the identification and interpretation of the results laid a good foundation for the next commercialization and industrialization.
  • Figure 1 is a strategic map of 14 functional KIR gene simultaneous sequencing typing techniques
  • the design uses 3 to 5 pairs of KIR gene-specific PCR primers (except KIR3DL3, which uses only 3 pairs of PCR primers for deletion of exon 6 and 5 pairs of PCR primers for KIR2DL1, and each of the functional KIR genes uses 4 pairs of PCR. Primers), specific PCR amplification of the entire coding region of each functional KIR gene. Purified PCR amplification products were passed through sixteen (KIR2DL1 ⁇ 5, 2DS1 ⁇ 5 and KIR3DL3) or eighteen (KIR3DL1 ⁇ 2 and KIR3DS1) specific forward and reverse sequencing primers for each exon. The sequence was subjected to a two-way sequencing reaction.
  • Fig. 2 is a diagram showing the effect of agarose gel electrophoresis of PCR amplification products of the KIRAA1 gene combination type sample of Example 1.
  • M DL2000 Marker
  • A1 Amplicon 1, amplifying the first exon to the second exon gene fragment
  • A2 Amplicon 2, amplifying the third exon of 3DL1 ⁇ 3, 3DS1, 2DL4 ⁇ 5 to A gene fragment of the exon 5 and a gene fragment of the exon 5 to exon 5 of KIR2DL1 to 3 and KIR2DS1 to 5.
  • KIR2DL1 uses two pairs of PCR primers to amplify the fourth exon (Amplicon 2-1) and the fifth exon (Amplicon 2-2); A3: Amplicon 3, amplify the gene of exon 6 Fragment; A4: Amplicon 4, amplifying a gene fragment from exon 7 to exon 9;
  • Figures 3-1 to 3-7 respectively correspond to the KIR2DL1, 2DL3, 2DL4, 2DS4, 3DL1, 3DL2, and 3DL3 full coding region sequencing sequences of the KIRAA1 gene combination sample of Example 1 and are introduced into Assign 3.5 or 4.7 analysis software renderings.
  • the KIR genotype of the sample is KIR2DL1*00302-2DL3*00101-2DL4*00102, 011-2DS4*00101, 010-3DL1*00501, 01502-3DL2*00201, 010-3DL3*00901, 010;
  • Fig. 4 is a graph showing the effect of agarose gel electrophoresis of PCR amplification products of the KIRAB6 gene combination type sample of Example 2.
  • M DL2000 Marker
  • A1 Amplicon 1, amplifying the first exon to the second Gene fragment of exon
  • A2 Amplicon 2, amplifying the 3rd exon to 3rd exon of 3DL1 ⁇ 3, 3DS1, 2DL4 ⁇ 5 and the 4th exon of KIR2DL1 ⁇ 3 and KIR2DS1 ⁇ 5 Gene fragment of the target to 5 exons.
  • KIR2DL1 uses two pairs of PCR primers to amplify the fourth exon (Amplicon 2-1) and the fifth exon (Amplicon 2-2); A3: Amplicon 3, amplify the gene of exon 6 Fragment; A4: Amplicon 4, amplifying a gene fragment from exon 7 to exon 9;
  • Figure 5-1 to Figure 5-14 show the effect of the sequence of 14 functional KIR gene coding regions of the KIRAB6 sample of Example 2 into the analysis software of Assign 3.5 or 4.7.
  • the KIR genotype of the sample is "KIR2DL1*00302,00401 -2DL2*00301-2DL3*00101-2DL4*00102,00501-2DL5A*00101,B*010-2DS1*00201-2DS2*00101-2DS3*00101-2DS4*00101-2DS5*00201-3DL1*01502-3DL2*00201 , 00701-3DL3*01002-3DS1*01301".
  • the KIR2DS4*001 homozygous sample was sequenced and the results showed that the 5th exon of the 2DS4*001 allele lacked 22bp. After the sequence was introduced, the 5th exon was forward sequenced in the coding region nt454 and downstream. Base misalignment ( Figure 5-9A), reverse sequencing also has no base misalignment at nt475 and upstream ( Figure 5-9B).
  • a sample of a KIRAA1 gene combination (KIR2DL1-2DL3-2DL4-2DS4-3DL1-3DL2-3DL3) detected by a commercial KIR-SSP kit was randomly selected, and 14 functional KIRs were performed on the sample using the present invention.
  • the genes were simultaneously sequenced to verify the effects of the present invention.
  • KIR gene-specific PCR amplification primers were used for PCR amplification of all coding regions of each functional KIR gene.
  • the amplification reaction was carried out on an ABI 9700 PCR machine.
  • the amplification reaction system consisted of:
  • the PCR amplification reaction can be synchronously amplified under the same cycle parameters, and the cycle parameters are:
  • the above seven KIR genes of the specific PCR amplification bands were detected by electrophoresis, and the PCR amplification products were further purified.
  • the purification reaction system consisted of:
  • the purification reaction of the PCR amplification product can be purified under the same cycle parameter conditions,
  • the loop parameters are:
  • the PCR product was diluted with 3 volumes of sterile deionized water and mixed well.
  • PCR products were electrophoretically detected for each KIR gene of the specific amplified band, and were specifically forward and reverse sequenced by sixteen (KIR2DL1, 2DL3, 2DL4, 2DS4, and KIR3DL3) or eighteen (KIR3DL1 ⁇ 2).
  • Primers, two-way sequencing reactions of purified and diluted amplification products, each sequencing reaction system is as follows:
  • the cycle parameters of the sequencing reaction are:
  • the sequencing product was purified by ethanol/NaOAc/EDTA precipitation method, and finally 15 ⁇ L of ultra-pure formamide solution (Hi-Di Formamide) was added and denatured at 95 ° C for 2.5 min on a PCR instrument.
  • the purified sequencing product was detected by capillary electrophoresis on an ABI 3730 gene sequencer and the sequence data information after electrophoresis was collected. All the sequences measured in this sample were introduced into Assign 3.5 or 4.7 (Conexio Genomics, Western Australia) analysis software (Fig.
  • Figure 3-4 shows the KIR2DS4*00101, 010 heterozygous sample sequencing results: 22 bp deletion in exon 5 of 2DS4*010 allele, and 22 bp deletion in 2DS4*00101, result 5 exon Forward sequencing occurred base misalignment at the nt454 and downstream positions of the coding region (Fig. 3-4A), and reverse sequencing revealed base misalignment at nt475 and upstream positions (Fig. 3-4B).
  • a sample of a KIRAA6 gene combination ie, carrying all 14 functional KIR genes
  • a commercial KIR-SSP kit was randomly selected, and 14 functional KIRs were performed on the sample using the present invention.
  • the genes were simultaneously sequenced to verify the effects of the present invention.
  • KIR gene-specific PCR amplification primers were used for PCR amplification of all coding regions of each functional KIR gene.
  • the amplification reaction was carried out on an ABI 9700 PCR machine.
  • the amplification reaction system consisted of:
  • the PCR amplification reaction can be synchronously amplified under the same cycle parameters, and the cycle parameters are:
  • Electrophoresis results showed that specific bands were detected in each of the 14 functional KIR genes including KIR2DL1, KIR2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, KIR2DS5, 3DL1, 3DL2, 3DL3 and 3DS1, in line with KIRAB6. Gene combination type.
  • the purification reaction of the PCR amplification product can be purified under the same cycle parameters, and the cycle parameters are:
  • the PCR product was diluted with 3 volumes of sterile deionized water and mixed well.
  • the PCR products were electrophoretically detected for each KIR gene of the specific amplified band, and were specifically forward and reverse by sixteen (KIR2DL1 ⁇ 5, 2DS1 ⁇ 5 and KIR3DL3) or eighteen (KIR3DL1 ⁇ 2 and KIR3DS1).
  • the sequencing primers are subjected to a two-way sequencing reaction on the purified and diluted amplification products, and each sequencing reaction system is as follows:
  • the cycle parameters of the sequencing reaction are:
  • the sequencing product was purified by ethanol/NaOAc/EDTA precipitation method, and finally 15 ⁇ L of ultra-pure formamide solution (Hi-Di Formamide) was added and denatured at 95 ° C for 2.5 min on a PCR instrument.
  • the purified sequencing product was detected by capillary electrophoresis on an ABI 3730 gene sequencer and the sequence data information after electrophoresis was collected.
  • Figure 5-9 shows the KIR2DS4*00101 homozygous sample sequencing results: the 5th exon of the 2DS4*00101 allele has no 22bp deletion. After the sequence is introduced, the 5th exon can be forward sequenced in the coding region nt454 and There was no base mislocation at the downstream position (Fig. 5-9A), and reverse sequencing also showed no base misalignment at nt475 and upstream (Fig. 5-9B).
  • This example gives an example of a population genetic survey using 14 functional KIR genes for simultaneous sequencing of 306 southern Han nationality health-independent individuals using the present invention.
  • KIR gene-specific PCR amplification primers were used for PCR amplification of all coding regions of each functional KIR gene.
  • the amplification reaction was carried out on an ABI 9700 PCR machine.
  • the amplification reaction system consisted of:
  • the PCR amplification reaction can be synchronously amplified under the same cycle parameters, and the cycle parameters are:
  • the purification reaction system consisted of:
  • the purification reaction of the PCR amplification product can be purified under the same cycle parameters, and the cycle parameters are:
  • the PCR product was diluted with 3 volumes of sterile deionized water and mixed well.
  • the PCR products were electrophoretically detected for each KIR gene of the specific amplified band, and were specifically forward and reverse by sixteen (KIR2DL1 ⁇ 5, 2DS1 ⁇ 5 and KIR3DL3) or eighteen (KIR3DL1 ⁇ 2 and KIR3DS1).
  • the sequencing primers are subjected to a two-way sequencing reaction on the purified and diluted amplification products, and each sequencing reaction system is as follows:
  • the cycle parameters of the sequencing reaction are:
  • the sequencing product was purified by ethanol/NaOAc/EDTA precipitation method, and finally 15 ⁇ L of ultra-pure formamide solution (Hi-Di Formamide) was added and denatured at 95 ° C for 2.5 min on a PCR instrument.
  • the purified sequencing product was detected by capillary electrophoresis on an ABI 3730 gene sequencer and the sequence data information after electrophoresis was collected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une méthode destinée à être utilisée dans l'amplification simultané et le séquençage et le génotypage simultanés des 14 gènes fonctionnels complets du récepteur de type immunoglobuline de cellules tueuses (KIR), qui est approprié pour des processus à débit élevé.
PCT/CN2017/081829 2017-04-25 2017-04-25 Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir) Ceased WO2018195765A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/081829 WO2018195765A1 (fr) 2017-04-25 2017-04-25 Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/081829 WO2018195765A1 (fr) 2017-04-25 2017-04-25 Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir)

Publications (1)

Publication Number Publication Date
WO2018195765A1 true WO2018195765A1 (fr) 2018-11-01

Family

ID=63917797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/081829 Ceased WO2018195765A1 (fr) 2017-04-25 2017-04-25 Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir)

Country Status (1)

Country Link
WO (1) WO2018195765A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339508A (zh) * 2013-05-09 2016-02-17 吉诺戴夫制药株式会社 Hla基因的多重dna分型方法和试剂盒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105339508A (zh) * 2013-05-09 2016-02-17 吉诺戴夫制药株式会社 Hla基因的多重dna分型方法和试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHEN, JIANXIN: "The Molecular Genetic Polymorphism of KIR in Southern Chinese Han Population and the Association with Leukemia", MEDICINE & PUBLIC HEALTH , CHINA MASTER'S THESES FULL-TEXT DATABASE, 15 December 2014 (2014-12-15), pages 44 - 45 *

Similar Documents

Publication Publication Date Title
US10266877B2 (en) Method for simultaneous sequence-based typing of 14 functional killer cell immunoglobulin-like receptor (KIR) genes
Fucharoen et al. Molecular basis of β-thalassemia in Thailand: analysis of β-thalassemia mutations using the polymerase chain reaction
CN111286541B (zh) 山羊zbp1基因3′utr内与产羔数关联的单倍型标记及其应用
CN107058538B (zh) 一种引物组合物及其组成的试剂盒和应用
CN104404164A (zh) 一种遗传性耳聋基因突变检测试剂盒
CN105296619A (zh) 中国人群肥胖易感基因snp分型用试剂盒及其使用方法
CN114182025B (zh) 与猪饲料转化率相关的snp分子标记及其应用
Gergics et al. Detection of the Bcl I polymorphism of the glucocorticoid receptor gene by single-tube allele-specific polymerase chain reaction
WO2021057667A1 (fr) Kit de génotypage pour détecter une déficience en gpiv provoquée par six gènes mutants cd36
WO2018195765A1 (fr) Méthode destinée à être utilisée dans le séquençage et le génotypage simultanés de 14 gènes fonctionnels de récepteur de type immunoglobuline de cellules tueuses (kir)
Gomez et al. Detection of deletions and duplications in the Duchenne muscular dystrophy gene by the molecular method MLPA in the first Argentine affected families
CN115927356B (zh) Slc45a2致病突变基因、致病突变体及在制备眼皮肤白化病ⅳ型诊断试剂盒中的应用
Nakayama et al. Alu-mediated 100-kb deletion in the primate genome: the loss of the agouti signaling protein gene in the lesser apes
Beutler et al. A common intron 3 mutation (IVS3− 48c→ g) leads to misdiagnosis of the c. 845G→ A (C282Y) HFE gene mutation
US20110104689A1 (en) Single nucleotide polymorphisms and the identification of lactose intolerance
CN116219035A (zh) 蒙古羊基因b4galnt2的分子标记的特异性引物及其应用
Zahari et al. A nested allele-specific multiplex polymerase chain reaction method for the detection of DRD2 polymorphisms
US7794982B2 (en) Method for identifying gene with varying expression levels
Cohen-Zinder et al. Multisite haplotype on cattle chromosome 3 is associated with quantitative trait locus effects on lactation traits
CN110904215A (zh) 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法
CN105200148B (zh) 一种辅助检测肉乳兼用牛胴体组成性状的方法及试剂盒
CN104342435B (zh) 猪背膘厚相关slc13a5基因的分子克隆及应用
Wang et al. Application of created restriction site PCR-RFLP to identify POT1 gene polymorphism
He et al. The C825T polymorphism in the G-protein beta 3 subunit gene in Chinese patients with preeclampsia
CN103114093B (zh) 猪连环蛋白α样1基因CTNNAL1作为猪产仔数性状的遗传标记

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17907071

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17907071

Country of ref document: EP

Kind code of ref document: A1